Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L-arginine

This article was originally published in The Tan Sheet

Executive Summary

"L-arginine therapy should not be given to patients following a myocardial infarction," a study in the Jan. 4 Journal of the American Medical Association concludes. Adding the supplement to standard post-MI drug therapy "did not reduce noninvasive measures of vascular stiffness, improve ejection fraction, or improve clinical outcomes," Steven Schulman, MD, Johns Hopkins Medical Institutions, et al., state. "We noted a possible increased risk of death in older patients after infarction while taking L-arginine compared with those taking a placebo." The randomized, double-blind, placebo-controlled trial was terminated early after the deaths of six patients in the L-arginine group. Increased risk of death in older patients may be due to age-related cardiovascular changes, such as endothelial dysfunction, the authors note...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098985

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel